PD-1/PD-L1免疫检查点在甲状腺疾病中的作用  

Roles of PD-1/PD-L1 immune checkpoint in thyroid diseases

作　　者：张国强 罗全勇[1] Zhang Guoqiang;Luo Quanyong(Department of Nuclear Medicine,Shanghai Jiao Tong University Affiliated Sixth People′s Hospital,Shanghai 200233,China)

机构地区：[1]上海交通大学附属第六人民医院核医学科,上海200233

出　　处：《中华核医学与分子影像杂志》2023年第2期118-121,共4页Chinese Journal of Nuclear Medicine and Molecular Imaging

基　　金：国家自然科学基金(81974271);上海市临床重点专科项目(shslczdzk03203)。

摘　　要：程序性细胞死亡受体1(PD-1)/PD-1配体(PD-L1)在维持正常组织免疫耐受和介导肿瘤免疫逃逸方面具有重要作用。对于自身免疫性甲状腺炎,甲状腺滤泡上皮细胞通过上调PD-L1表达来抑制T细胞对甲状腺组织的损伤作用。随着免疫检查点抑制剂(ICIs)在肿瘤治疗中的应用增多,由ICIs引起的免疫相关性甲状腺功能紊乱的发生率增加。在ICIs治疗期间和治疗结束后,应监测甲状腺功能,及时诊断原发性和(或)继发性甲状腺功能紊乱。PD-1/PD-L1对甲状腺癌细胞发挥直接刺激作用,对肿瘤浸润的免疫细胞发挥抑制作用。靶向PD-1/PD-L1的ICIs与放化疗、靶向治疗联合策略在难治性甲状腺癌治疗中具有良好前景。Programmed cell death receptor 1(PD-1)/PD-1 ligand(PD-L1)maintains immune tolerance of normal tissues and mediates immune escape of tumors.For autoimmune thyroiditis,thyroid follicular epithelial cells inhibit the damage of T cells by up-regulating PD-L1 expression.With the application of immune checkpoint inhibitors(ICIs)in the field of cancer therapy,the incidence of immune-related thyroid disorders caused by ICIs has increased.Thyroid function should be monitored during and after ICIs treatment to promptly diagnose primary and(or)secondary thyroid disorders.The PD-1/PD-L1 signaling directly stimulates thyroid cancer cells,and exerts inhibitory effects on tumor-infiltrating immune cells.Combination of ICIs targeting PD-1/PD-L1 with chemo-radiotherapy or targeted therapy is a promising therapeutic strategy in the treatment of refractory thyroid cancers.

关 键 词：甲状腺疾病 免疫检查点抑制剂 程序性细胞死亡受体1 发展趋势 

分 类 号：R581[医药卫生—内分泌]